Albireo and Biodel merged to form Albireo Pharma Inc. (NASDAQ:ALBO, Boston, Mass.). The company plans to start a pivotal trial of lead compound A4250 next year to treat progressive familial intrahepatic cholestasis (PFIC). A4250 is...

In January, Biodel reduced headcount by 15 non-executive employees to preserve cash. The company expects to reduce average operating cash burn to about $1.1 million from $4.5 million per quarter. Biodel declined to disclose how...

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...

Biodel will reduce headcount by 10 (30%) to about 23 and restructure research and quality-related activities to focus on later-stage clinical development programs. The company expects the restructuring to save about $2 million annually. In...

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...